A263050 Share Price Performance
₩1,739.00
-1081.00 (-38.33%)
Price ₩1,739.00
Share Price₩1,739.00
A263050 Community Narratives
There are no narratives available yet.
Recent A263050 News & Updates
No updates
Eutilex.Co.,Ltd Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -753.05
- Gross Margin
- 4.67%
- Net Profit Margin
- -246.54%
- Debt/Equity Ratio
- 43.7%
Eutilex.Co.,Ltd Competitors
About A263050
- Founded
- 2008
- Employees
- 141
- CEO
- WebsiteView website
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -1.1%
- 3 Months: 22.2%
- 1 Year: 23.5%
- Year to Date: 30.6%
Over the last 7 days, the market has dropped 1.1%, driven by a loss of 5.7% in the Materials sector. As for the longer term, the market has actually risen by 24% in the last year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading